- call +1-201-465-4211
- email sales@mrinsights.biz
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Scope of the Report:
This report studies the Onychomycosis (Tinea Unguium) Drug market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Onychomycosis (Tinea Unguium) Drug market by product type and applications/end industries.
The classification of Onychomycosis (Tinea Unguium) Drug Oral medication and External medicine, and the proportion of Oral medication in 2016 is about 76.24% market share is in decrease trend.
Onychomycosis (Tinea Unguium) Drug are widely used for Age under 18, Age 18-50 and Age above 50 treatment. The most proportion of consumer is in Age 18-50, and the market share in 2016 is 82.66%.
USA is the largest consumption place, with a consumption market share nearly 33.14% in 2016. Following USA, Europe is the second largest consumption place with the consumption market share of 23.66%.
The global Onychomycosis (Tinea Unguium) Drug market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Onychomycosis (Tinea Unguium) Drug.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Johnson & Johnson
GSK
Novartis
Pfizer
Valeant Pharma
Kaken Pharmaceutical
Galderma
Xiuzheng Pharmaceutical
Letai
Qilu Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Oral Medication
External Medicine
Market Segment by Applications, can be divided into
Age Under 18
Age 18-50
Age Above 50
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Onychomycosis (Tinea Unguium) Drug Market Overview
1.1 Product Overview and Scope of Onychomycosis (Tinea Unguium) Drug
1.2 Classification of Onychomycosis (Tinea Unguium) Drug by Types
1.2.1 Global Onychomycosis (Tinea Unguium) Drug Revenue Comparison by Types (2017-2023)
1.2.2 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Types in 2017
1.2.3 Oral Medication
1.2.4 External Medicine
1.3 Global Onychomycosis (Tinea Unguium) Drug Market by Application
1.3.1 Global Onychomycosis (Tinea Unguium) Drug Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Age Under 18
1.3.3 Age 18-50
1.3.4 Age Above 50
1.4 Global Onychomycosis (Tinea Unguium) Drug Market by Regions
1.4.1 Global Onychomycosis (Tinea Unguium) Drug Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Onychomycosis (Tinea Unguium) Drug Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Onychomycosis (Tinea Unguium) Drug Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Onychomycosis (Tinea Unguium) Drug Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Onychomycosis (Tinea Unguium) Drug Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Onychomycosis (Tinea Unguium) Drug Status and Prospect (2013-2023)
1.5 Global Market Size of Onychomycosis (Tinea Unguium) Drug (2013-2023)
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Business Overview
2.1.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Johnson & Johnson Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.2 GSK
2.2.1 Business Overview
2.2.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GSK Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.5 Valeant Pharma
2.5.1 Business Overview
2.5.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.6 Kaken Pharmaceutical
2.6.1 Business Overview
2.6.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.7 Galderma
2.7.1 Business Overview
2.7.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Galderma Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.8 Xiuzheng Pharmaceutical
2.8.1 Business Overview
2.8.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.9 Letai
2.9.1 Business Overview
2.9.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Letai Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
2.10 Qilu Pharmaceutical
2.10.1 Business Overview
2.10.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2016-2017)
3 Global Onychomycosis (Tinea Unguium) Drug Market Competition, by Players
3.1 Global Onychomycosis (Tinea Unguium) Drug Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Onychomycosis (Tinea Unguium) Drug Players Market Share
3.2.2 Top 10 Onychomycosis (Tinea Unguium) Drug Players Market Share
3.3 Market Competition Trend
4 Global Onychomycosis (Tinea Unguium) Drug Market Size by Regions
4.1 Global Onychomycosis (Tinea Unguium) Drug Revenue and Market Share by Regions
4.2 North America Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
4.3 Europe Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
4.5 South America Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
5 North America Onychomycosis (Tinea Unguium) Drug Revenue by Countries
5.1 North America Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2013-2018)
5.2 USA Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
5.3 Canada Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
5.4 Mexico Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
6 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Countries
6.1 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2013-2018)
6.2 Germany Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
6.3 UK Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
6.4 France Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
6.5 Russia Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
6.6 Italy Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Revenue by Countries
7.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2013-2018)
7.2 China Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
7.3 Japan Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
7.4 Korea Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
7.5 India Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
8 South America Onychomycosis (Tinea Unguium) Drug Revenue by Countries
8.1 South America Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2013-2018)
8.2 Brazil Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
8.3 Argentina Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
8.4 Colombia Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Onychomycosis (Tinea Unguium) Drug by Countries
9.1 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2013-2018)
9.2 Saudi Arabia Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
9.3 UAE Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
9.4 Egypt Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
9.5 Nigeria Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
9.6 South Africa Onychomycosis (Tinea Unguium) Drug Revenue and Growth Rate (2013-2018)
10 Global Onychomycosis (Tinea Unguium) Drug Market Segment by Type
10.1 Global Onychomycosis (Tinea Unguium) Drug Revenue and Market Share by Type (2013-2018)
10.2 Global Onychomycosis (Tinea Unguium) Drug Market Forecast by Type (2018-2023)
10.3 Oral Medication Revenue Growth Rate (2013-2023)
10.4 External Medicine Revenue Growth Rate (2013-2023)
11 Global Onychomycosis (Tinea Unguium) Drug Market Segment by Application
11.1 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2013-2018)
11.2 Onychomycosis (Tinea Unguium) Drug Market Forecast by Application (2018-2023)
11.3 Age Under 18 Revenue Growth (2013-2018)
11.4 Age 18-50 Revenue Growth (2013-2018)
11.5 Age Above 50 Revenue Growth (2013-2018)
12 Global Onychomycosis (Tinea Unguium) Drug Market Size Forecast (2018-2023)
12.1 Global Onychomycosis (Tinea Unguium) Drug Market Size Forecast (2018-2023)
12.2 Global Onychomycosis (Tinea Unguium) Drug Market Forecast by Regions (2018-2023)
12.3 North America Onychomycosis (Tinea Unguium) Drug Revenue Market Forecast (2018-2023)
12.4 Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Revenue Market Forecast (2018-2023)
12.6 South America Onychomycosis (Tinea Unguium) Drug Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Onychomycosis (Tinea Unguium) Drug Picture
Table Product Specifications of Onychomycosis (Tinea Unguium) Drug
Table Global Onychomycosis (Tinea Unguium) Drug and Rev
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
